Articles tagged with Subcutaneous Injections
The researchers have created a way to deliver certain drugs in higher doses with less pain by injecting them as a suspension of tiny crystals. This approach can enable long-term delivery of contraceptives or treatments for diseases such as HIV, reducing the need for frequent injections.
Research finds that people who use illicit opioids are at risk of developing severe xylazine-related wounds, often due to lack of access to proper wound care. The study highlights the need for comprehensive, low-barrier wound care services and compassionate care without judgment.
Researchers at MIT and Brigham and Women's Hospital have developed an implantable device that monitors vital signs and releases naloxone to reverse opioid overdoses. The device has shown success in reversing overdoses in animals, with a 96% recovery rate.
A new nanofluidic implant has been shown to deliver an HIV drug with increased potency compared to existing oral medications, providing a potential breakthrough in addressing treatment nonadherence. The device is intended for long-term controlled release and avoids repeated systemic treatment, which can lead to adverse side effects.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
A single dose of zilebesiran safely and effectively lowered systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months. The study found significant reductions in daytime and nighttime systolic blood pressure, as well as low rates of adverse events.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.
Recent review article discusses clinical development in long-acting growth hormone (LAGH) therapy, which mimics natural GH release patterns. LAGH therapies reduce daily injection burden, improving patient compliance and treatment outcomes.
A new cutaquig study found that increasing infusion volume per site resulted in a reduction of injection sites, while increasing infusion rates decreased infusion duration. The research also showed that dosing every other week demonstrated equivalency to trough levels with weekly dosing.
Researchers at the University of Maryland School of Medicine found that monoclonal antibody CIS43LS provided high levels of protection against controlled human malaria infection. The study's findings suggest that this treatment could be a potential game changer for deploying monoclonal antibody therapies in African countries.
Scientists at Nanyang Technological University have developed a novel therapeutic approach to tackle obesity, reducing body fat and improving blood markers through a hydrogel injection and near infrared light treatment. The treatment shows significant promise in lab trials, with mice experiencing reduced body mass and improved metabolism.
The Liberty Asthma VOYAGE trial found that dupilumab significantly reduced the rate of severe exacerbations by nearly 60% and improved lung function and asthma control in children ages 6 to 11. Dupilumab was also shown to be safe, with minimal adverse reactions.
A wearable device has been developed to detect and reverse opioid overdoses by injecting naloxone, a lifesaving antidote. The device, which senses when a person stops breathing and moving, has shown promising results in clinical trials.
A randomized trial shows that subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin in treating venous thromboembolism. The study found comparable rates of recurrent thromboembolism and major bleeding between the two groups.
Researchers found that injecting methotrexate significantly improved patient health and reduced costs for those with juvenile rheumatoid arthritis or rheumatoid arthritis. The study involved 52 patients, with 73% switching to injection treatment due to dissatisfaction with oral method side effects.